CBtru®, a drug delivery solution for oral solid dosage forms

Formulating a highly lipophilic and poorly soluble crystalline molecule, such as cannabidiol (CBD), can be a complex task. In fact, the oral bioavailability of CBD can be as low as 6% in humans, as a result of incomplete absorption in the gut and significant pre-systemic elimination in the liver. This has slowed the development of patient-friendly solid oral dosage forms—until now.CBtru®, an innovative, patent-pending drug delivery solution, is making a new era in drug formulation possible—one that unlocks the true potential of highly lipophilic molecules, like CBD. Enabling optimized bioavailability in solid oral dosage forms is paving the way for more patient-friendly delivery systems, such as tablets and capsules. This will help increase patient convenience and compliance, and elevate patient care worldwide.